E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
INCYTE  
INCYTE
INCYLast: $13.74 ($+0.06)Volume: 1,529,343Last Trade: 8/5/2010 5:20:01 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
NASDAQ:INCY $13.74 ($+0.06 +0.4385%)
Industry: Health Sector: Biotechnology
Open: 13.69 Previous Close: 13.68
Day's High: 13.97 Day's Low: 13.43
52-Week High: 12.72 52-Week Low: 4.75
 
Bid: 13.75 / 700 Ask: 13.76 / 900
Volume: 1,529,343 Outstanding: 0
Market Cap: -
INCYTE Profile
Incyte is a drug discovery and development company focused on developing proprietary small molecule drugs. As of Dec 31 2006, Co.'s pipeline included compounds that target human immunodeficiency virus (HIV), diabetes, oncology (solid tumors and myeloproliferative disorders and cancer) and inflammation (multiple sclerosis, lupus nephritis, and inflammation). At Dec 31 2006, Co.'s compounds included: CCR5 Antagonist Program for HIV; 11 HSD1 Program for Type 2 Diabetes and Related Disorders; CCR2 Receptor Antagonist Program for Inflammatory Diseases; JAK 2 Program for Inflammatory Diseases, Myeloproliferative Disorders and Cancer; as well as Sheddase Inhibitor Program for Solid Tumors.
 INCYTE News & Press Releases

Results from an Ongoing Phase I/II Trial of Oral INCB7839 Presented at ASCO
Incyte Corporation ( INCY ) announced today additional positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, IN... [more]

Incyte Appoints Wendy Dixon, Ph.D., to Its Board of Directors
Incyte Corporation ( INCY ) announced that Wendy Dixon, Ph.D., former Chief Marketing Officer and President, Global Marketing at Bristol-Myers Squibb Company (... [more]

Incyte Announces Redemption of Its 3% Convertible Senior Notes Due 2011 and Its 3% Convertible Sub
Incyte Corporation ( INCY ) today announced that it will redeem all of its outstanding 3% Convertible Senior Notes due 2011 and all of its outstanding 3% Con... [more]

Incyte to Present at the 28th Annual JPMorgan Healthcare Conference
Incyte Corporation ( INCY ) announced today it will present at the 28 th Annual JPMorgan Healthcare Conference on Tuesday, January 12, 2010 at 9:30... [more]

Data from a Phase I/II Study Presented at the 32nd San Antonio Breast Cancer Symposium Suggest that
Incyte Corporation ( INCY ) announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, inv... [more]

Incyte to Host Webcast at 51st American Hematology Annual Meeting
Incyte Corporation ( INCY ) announced today that it has scheduled a webcast for 8:30 p.m. CT / 9:30 p.m. ET on Monday, December 7, 2009 to discuss clinical res... [more]

Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs
Incyte Corporation ( INCY ) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematol... [more]

Incyte to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
Incyte Corporation ( INCY ) announced today it will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Monday, October 5, 2009 at 10:30... [more]

Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock
Incyte Corporation ( INCY ) today announced the pricing of its underwritten public offering of 18,000,000 shares of its common stock at a price to the public o... [more]

Incyte Prices $350 Million Convertible Senior Notes Offering
Incyte Corporation ( INCY ) today announced the pricing of its offering of $350 million aggregate principal amount of 4.75% Convertible Senior Notes due 2015 i... [more]

Incyte Announces Proposed Offering of $250 Million Convertible Senior Notes
Incyte Corporation ( INCY ) today announced that it intends to offer, subject to market and other conditions, up to $250 million aggregate principal amount of... [more]

Incyte Announces Proposed Public Offering of 18,000,000 Shares of Common Stock
Incyte Corporation ( INCY ) today announced that it intends to offer to sell, subject to market and other conditions, 18,000,000 shares of its common stock in... [more]

Incyte to Present at Upcoming Investor Conferences
Incyte Corporation ( INCY ) announced today it will present at the following investor conferences: Baird 2009 Health Care Conference on Wedne... [more]

Incyte to Present at Citi's 4th Annual Biotech Day Conference
Incyte Corporation ( INCY ) announced today it will present at Citi's 4 th Annual Biotech Day Conference on Wednesday, April 1, 2009 at 11:20 a.m.... [more]

Incyte to Report 2008 Financial Results and 2009 Financial Guidance and Provide Update on Drug Disco
Incyte Corporation ( INCY ) announced today that it has scheduled its fourth quarter and year-end 2008 financial results conference call for 8:30 a.m. ET on We... [more]

Incyte to Present at the 27th Annual JPMorgan Healthcare Conference
Incyte Corporation ( INCY ) announced today it will present at the 27 th Annual JPMorgan Healthcare Conference on Tuesday, January 13, 2009 at 3:30... [more]

Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits i
Incyte Corporation ( INCY ) will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibi... [more]

Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference
Incyte Corporation ( INCY ) announced today it will present at the 20 th Annual Piper Jaffray Health Care Conference on Wednesday, December 3, 2008... [more]

Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Pa
Incyte Corporation ( INCY ) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase... [more]

Incyte to Present at JMP Securities Third Annual Healthcare Focus Conference
Incyte Corporation ( INCY ) announced today it will present at the JMP Securities Third Annual Healthcare Focus Conference on Monday, October 6, 2008 at 11:00... [more]

Incyte Appoints Chief Commercial Officer
Incyte Corporation ( INCY ) announced today the appointment of Patricia S. Andrews as executive vice president and chief commercial officer, a new position rep... [more]

Incyte to Present at the UBS Global Life Sciences Conference
Incyte Corporation ( INCY ) announced today it will present at the 2008 UBS Global Life Sciences Conference on Tuesday, September 23, 2008 at 8:00 a.m. (Easter... [more]

Incyte to Present at Upcoming Investor Conferences
Incyte Corporation ( INCY ) announced today it will present at the following investor conferences: 3 rd Annual Citi... [more]

Incyte Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock
Incyte Corporation ( INCY ) today announced the pricing of its underwritten public offering of 10,500,000 shares of its common stock at a price to the public o... [more]

Incyte to Report Second Quarter 2008 Financial Results and Provide Update on Drug Discovery & Develo
Incyte Corporation ( INCY ) announced today that it has scheduled its second quarter 2008 financial results conference call for 8:30 a.m. ET on Thursday, July... [more]

Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity an
Incyte Corporation ( INCY ) announced clinical results presented today at the American Diabetes Association 68th Scientific Sessions of its Phase IIa trial of... [more]

Incyte to Present at Upcoming Investor Conferences
Incyte Corporation ( INCY ) announced today it will present at the following investor conferences: Goldman Sachs Twenty-Ninth Annual Global H... [more]

QED International Associates Announces Quarterly Rebalancing of ...
PR Newswire (press release): QED International Associates Announces Quarterly Rebalancing of ... , NY - Mar 20, 2008 NASDAQ: ENZN Exelixis Inc. NASDAQ: EXEL Flamel Technologies NASDAQ: FLML Illumina Inc. NASDAQ: ILMN Incyte Corporation NASDAQ: INCY Integra Lif

NEW YORK, March 20 --
Biloxi Sun Herald: ,  USA - Mar 20, 2008 (Nasdaq: ENZN) Exelixis Inc. (Nasdaq: EXEL) Flamel Technologies (Nasdaq: FLML) Illumina Inc. (Nasdaq: ILMN) Incyte Corporation ( Nasdaq: INCY ) Integra ...

NEW YORK, March 19 --
Biloxi Sun Herald: ,  USA - Mar 19, 2008 (Nasdaq: ENZN) Exelixis Inc. (Nasdaq: EXEL) Flamel Technologies (Nasdaq: FLML) Illumina Inc. (Nasdaq: ILMN) Incyte Corporation ( Nasdaq: INCY ) Integra ...

Incyte to Provide Update on Clinical Programs at Cowen Health Care ...
PR-Inside.com (Pressemitteilung): Incyte to Provide Update on Clinical Programs at Cowen Health Care ... , Austria - Mar 18, 2008 ... Investor Relations/Corporate Communications 302/498-6944 Incyte Corporation ( Nasdaq:INCY ) will announce today at the Cowen and Comp


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts